ID   MAVER-1
AC   CVCL_1831
SY   Maver-1; MAVER1; Maver1; MAVER; MAntle cell VERona-1
DR   ATCC; CRL-3008
DR   BioSample; SAMN03471709
DR   Cosmic; 2078182
DR   Cosmic; 2088018
DR   DSMZ; ACC-717
DR   GEO; GSM1044978
DR   GEO; GSM1044979
DR   GEO; GSM1044980
DR   GEO; GSM1044981
DR   GEO; GSM1266781
DR   GEO; GSM1266782
DR   GEO; GSM1266793
DR   GEO; GSM1266794
DR   GEO; GSM1266795
DR   GEO; GSM1266796
DR   GEO; GSM1266797
DR   GEO; GSM1266798
DR   GEO; GSM2322621
DR   IARC_TP53; 24552
DR   Wikidata; Q54904067
RX   PubMed=16434369;
RX   PubMed=24362935;
RX   PubMed=25315077;
RX   PubMed=25688540;
RX   PubMed=25960936;
RX   PubMed=27697772;
RX   PubMed=29666304;
CC   Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC   Doubling time: 24 hours (PubMed=25315077); ~48 hours (DSMZ).
CC   HLA typing: A*68:01,02:01; B*55:01,07:02; C*03:03,07:02; DQA1*05:01,02:01; DQB1*03:01,02:01; DRB1*11:01,07:01 (PubMed=25960936).
CC   HLA typing: A*24,26; B*38,44; C*05,12 (PubMed=25688540).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Glu (c.843C>G); ClinVar=VCV000376587; Zygosity=Hemizygous (PubMed=16434369).
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): ATCC; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,13
ST   D16S539: 9,12
ST   D5S818: 12
ST   D7S820: 8
ST   TH01: 8,9
ST   TPOX: 8,12
ST   vWA: 14,18
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   82Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 20
//
RX   PubMed=16434369;
RA   Zamo A., Ott G., Katzenberger T., Adam P., Parolini C., Scarpa A.,
RA   Lestani M., Menestrina F., Chilosi M.;
RT   "Establishment of the MAVER-1 cell line, a model for leukemic and
RT   aggressive mantle cell lymphoma.";
RL   Haematologica 91:40-47(2006).
//
RX   PubMed=24362935; DOI=10.1038/nm.3435;
RA   Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chan F.C.,
RA   Meissner B., Bhang H.-E., Ruddy D., Kauffmann A., Farsidjani A.,
RA   Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S.,
RA   Dietze K., Dorken B., Steidl C., Tzankov A., Hummel M., Monahan J.,
RA   Morrissey M.P., Fritsch C., Sellers W.R., Cooke V.G., Gascoyne R.D.,
RA   Lenz G., Stegmeier F.;
RT   "Pharmacological and genomic profiling identifies NF-kappaB-targeted
RT   treatment strategies for mantle cell lymphoma.";
RL   Nat. Med. 20:87-92(2014).
//
RX   PubMed=25315077; DOI=10.3109/10428194.2014.970548;
RA   Fogli L.K., Williams M.E., Connors J.M., Reid Y.A., Brown K.,
RA   O'Connor O.A.;
RT   "Development and characterization of a Mantle Cell Lymphoma Cell Bank
RT   in the American Type Culture Collection.";
RL   Leuk. Lymphoma 56:2114-2122(2015).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=27697772; DOI=10.1182/blood-2016-06-720490;
RA   Chiron D., Bellanger C., Papin A., Tessoulin B., Dousset C., Maiga S.,
RA   Moreau A., Esbelin J., Trichet V., Chen-Kiang S., Moreau P.,
RA   Touzeau C., Le Gouill S., Amiot M., Pellat-Deceunynck C.;
RT   "Rational targeted therapies to overcome microenvironment-dependent
RT   expansion of mantle cell lymphoma.";
RL   Blood 128:2808-2818(2016).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S., Pogue E.,
RA   Ding Z., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J.,
RA   Ford R.J., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//